Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KR233
- Development stage
- Preclinical
- Lead developer
- Jiangxi Kvvit Pharmaceutical
- Modality
- Small Molecules
01
Overview
KR233 is an investigational drug candidate currently under development by Jiangxi Kvvit Pharmaceutical (also known as Qingfeng Pharmaceutical Group). As of early 2024, the candidate is in the IND-enabling phase, transitioning from preclinical candidate (PCC) status toward Phase 1 clinical trials. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, the drug is categorized within the company's pipeline under Central Nervous System (CNS) and other therapeutic areas. The 'KR' designation typically refers to candidates discovered by the company's Kunrui research division, which primarily focuses on small molecule discovery.
Beyond the preview
Go deeper on KR233.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KR233.